tbuckley/cabot-search huggingface dataset:
Patterns of care in patients treated a community cancer center for non small cell lung cancer
Authors: K. R. Oettel, J. E. Schroeder, M. A. Mathiason
Journal: Journal of Clinical Oncology (2008)

17550 Background: The vast majority of patients with lung cancer are treated in a community setting. Patients with Non Small Cell Lung Cancer (NSCLCA) can have a poor prognosis with variability in their care. We sought to assess care patterns from the years of 2004–2005 at a community cancer center. Methods: 208 patients with NSCLCA were seen and treated at a community cancer center from January 2004 through December 2005. We evaluated their care with regard to NCCN guidelines and assessed overall survival. Results: Of the 208 patients seen, 128 patients had advanced stage IIIB or IV disease (61.5%). Eighty (80) patients with stage IA - IIIA disease were seen and 47 underwent surgical resection (59%). For patients with stage IA-IIB disease 43 patients of 54 underwent surgical resection (80%), however only 4 of 24 patients with stage IIIA disease were able to undergo surgical resection (15%). Nearly all patients with stage IA - IIIA who did not undergo surgical resection were deemed unresectable based on comorbities, not patient choice. For patients with stage IB - IIIA disease that were able to undergo surgical resection, administration of adjuvant chemotherapy rose sharply from 2004 to 2005 from 7.1% to 53.3% respectively (P=0.007). For patients with unresectable stage IB-IIIA disease 21 of 29 (72%) received palliative chemotherapy. Overall twenty four patients were enrolled on clinical trials (11.5%). Median survival for patients with stages IB to IIIA is 25.9 months for females vs 21.7 months for males. For patients with IIIB to IV disease females had a median survival of 6.2 months vs. 5.2 months for males (P=0.151). Conclusions: Patients with IIIA disease were much less likely to undergo surgical resection than patients with earlier stage disease. Adjuvant chemotherapy has been incorporated into practice representative of national practice patterns and NCCN guidelines. Median survivals are below national averages perhaps corresponding to the patient population seen at community cancer centers. No significant financial relationships to disclose.
Quality of life (QOL) assessment with EORTC QLQ-C30 in daily clinical practice
Authors: R. Bascioni, F. Giorgi, B. Esperide, D. Iacopini, M. Brugni, L. Giustini, G. de Signoribus
Journal: Journal of Clinical Oncology (2005)

8205 Background: Regular measurement of QOL in cancer patients (pts) seems to improve patient-physician communication and symptom control. Few studies evaluated feasibility and compliance of QOL questionnaires outside clinical trials during routine clinical practice in oncology. Methods: Aim of the study was to assess the compliance of a systematic approach of measuring QOL in cancer pts. Consecutive cancer outpatients scheduled for chemotherapy in two oncology clinics were included in the study; they received the EORTC QLQ C-30 questionnaire (validated Italian version) in the medical oncology clinic during waiting time before receiving IV therapy. The questionnaires were presented to pts by a medical oncologist or by a psychologist. Patients who did not complete or had problems with the assessment were analyzed for causes of non-compliance. Results: During two weeks 165 pts were approached, F 107 M 58, median age 66 years (range 34–84), education level: primary school 96 pts, middle school 37, high school 25 pts, graduate 5 pts, PS ECOG 0 = 93 pts, 1 = 40 pts, 2 = 21 pts, 3 = 11. Main tumour types: breast 45, colorectal 39, lung 30. One hundred fifty-five pts (94%) received intravenous chemotherapy or immunotherapy. Questionnaires were correctly completed by 62 pts (37%); 67 pts (41%) needed help from health care staff, 21 pts from family members, 5 pts returned an incomplete questionnaire, 10 pts refused evaluation. Causes of help request in QOL evaluation were: writing or reading problems in 54 pts (33%), inability to understand some questions in 37 pts (22%). Main questions not understood in the QLQ C-30 were: n° 30 (28 pts), n° 29 (12 pts), n° 27 (12 pts). Reasons for refusal of QOL evaluation were: low PS (6 pts), cognitive impairment (2 pts), simple refusal (2 pts). Conclusions: Collection of QOL data outside clinical trials is a difficult task; we observed a low number (37%) of fully compliant pts with EORTC QLQ C-30. We are considering the application of more simple and less time consuming QOL instruments in clinical practice in order to increase compliance. No significant financial relationships to disclose.
A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results
Authors: W. K. Oh, J. Manola, R. W. Ross, A. Berkowitz, C. W. Ryan, K. M. Eilers, T. M. Beer
Journal: Journal of Clinical Oncology (2006)

14533 Background: Treatment options for HRPC patients who progress after docetaxel chemotherapy are limited. Carboplatin may enhance the efficacy of docetaxel chemotherapy. Methods: We prospectively treated HRPC patients with documented PSA or radiographic progression during a minimum of 2 cycles of docetaxel-based chemotherapy or within 45 days of completing therapy. No prior platinum was allowed, though patients may have received other prior chemotherapy. Patients received docetaxel 60 mg/m 2 and carboplatin AUC (4) every 21 days until progression or unacceptable toxicity. Measurable response was assessed by RECIST criteria. PSA declines were assessed per PSA Working Group; 2 patients were not evaluable as they received only 1 cycle of therapy but are included in the denominator. Results: Interim data is available on the 1st stage of patients (n = 16) enrolled in this ongoing phase II trial. Median age was 69 years (range 46–81), 94% white. Baseline performance status was 0 or 1 in 88%. Prior therapies included antiandrogens (80%) and ketoconazole (47%); docetaxel was used alone (33%), with estramustine (33%) or another agent (33%). Median PSA at baseline was 44 ng/ml (range 4.9–4801). Patients received a median of 3 cycles of docetaxel/carboplatin (range 1–12+). PSA declines of ≥50% were noted in 3 of 16 patients (19%, 90% C.I. 5–42%). In addition, 5 patients had SD, suggesting clinical benefit in 50% (90% C.I. 28–72%). Of 10 patients with measurable disease at baseline, 2 (20%; 90% C.I. 4–51%) had confirmed PR. Therapy was well-tolerated, with no treatment-related deaths and five grade 3 toxicities, including anemia (1), leukopenia (3) and hyperglycemia (1). Median time to progression was 2.7 months (range 0–13.4); median survival was 11.7 months (95% C.I. 6.7–14.0). Conclusions: In preliminary analyses, docetaxel plus carboplatin demonstrated encouraging activity in patients who progressed after docetaxel-based therapy. PSA declines ≥50% were seen in 19%; measurable responses in 20%. Accrual is ongoing. Final analyses will include correlation of response to serum markers of neuroendocrine differentiation. (Supported by BMS). No significant financial relationships to disclose.
Feasibility of weekly paclitaxel/carboplatin for ovarian or peritoneal cancer patients with poor performance status
Authors: M. Yunokawa, N. Katsumata, E. Nakano, K. Yonemori, T. Kouno, C. Shimizu, K. Tamura, M. Ando, Y. Fujiwara
Journal: Journal of Clinical Oncology (2008)

16567 Background: To assess the feasibility of weekly paclitaxel/ carboplatin as a first line chemotherapy among poor performance status (PS) patients (pts) with advanced ovarian or peritoneal cancer. Methods: Clinical data was reviewed retrospectively by medical chart from 2001 to 2007. We evaluated poor PS pts who were administered the chemotherapy regimen of paclitaxel 80mg/m2 and carboplatin AUC 2 on day 1, 8, 15 every 21 days. Results: Thirteen pts had evaluated as clinical stage of stage IIIc (3 pts) and IV (10 pts), PS 3 (6 pts) and 4 (7 pts) and median age 63 years old (range, 44–77). The major reason which made poor PS were pleural and/or peritoneal effusion (9 pts), bowel obstruction (3 pts) and bone metastasis (1 pts). Median number of chemotherapy cycle was 1 (range, 1–6). Response rate was 31% (4/13) of which 4 patients with 2 complete and 2 partial response could be receive the 6 cycles and recover PS. Out of 9 patients who could not continue the chemotherapy, 6 pts had severe bowel obstruction. None of 4 responders had bowel obstruction. The median overall survival was 1.8 (range, 0.7–57) and 4 responders and 9 non responders were 12 months (range, 4–57) and 1.1 months (range, 0.7–15) respectively. The major toxicities graded 3/4 were occurred as leucopenia: 76.9%(10/13), neutropenia: 76.9%(10/13), anemia: 61.5%(8/13) and thrombocytopenia: 30.8%(4/13). Six patients (46%) died within 2 weeks after the last chemotherapy because of septic shock, and 4 of them had severe bowel obstruction. Conclusions: Advanced ovarian cancer patients with poor PS may have a less chance of treatment continuation because of severe toxicity and disease progression. Especially sever bowel obstruction can be the fatal toxicity. Paradoxically, chemotherapy can be the only way to survive for these patients who has poor PS. We should evaluate the patients on ahead and give chemotherapy carefully. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bristol-Myers Squibb, Kyowa Hakko Kogyo, Nippon Kayaku, Pfizer Oncology, sanofi-aventis
Reducing patient suffering and preventing readmissions via supportive care screening: The James Cancer Hospital supportive-care screening model.
Authors: Sharla Wells-Di Gregorio, Alexandra Zaleta, Emily Porensky, Lisa Graham, Kelly McDowell, Janet Snapp
Journal: Journal of Clinical Oncology (2014)

33 Background: Hospital admissions create physical, financial and emotional stress for oncology patients. Hospital avoidable readmissions are considered a marker of poorer quality patient care. To reduce readmissions, cancer hospitals must understand modifiable readmission risk factors AND establish screening systems to triage at-risk patients to outpatient palliative/supportive care services. The James Cancer Hospital is in Phase II development of a model to reduce patient suffering and readmission via the James Supportive Care Screening (JSCS), a 48-item validated clinical-research instrument. Methods: In 2013, the James Cancer Hospital began implementation of Supportive Care Screening to meet Standard 3.2 (Psychosocial Distress Screening) of the Commission on Cancer. The JSCS asks patients to rate distress in six palliative care domains including emotional concerns, physical symptoms, social/practical problems, spiritual problems, cognitive concerns, and healthcare decision-making/communication issues. Between January 2011 and December 2013, one-thousand and one patients completed the JSCS in the Outpatient Palliative Care clinic. During this period, 57 patients had at least one readmission. Hierarchical linear regression was used to predict the number of future readmissions with JSCS subscales as independent variables. Results: The overall model predicting readmissions was significant, F(7,959) = 37.074, p&lt;.001. Time to readmission, physical symptoms, emotional concerns, spiritual concerns, and social concerns were significant predictors of patient readmission. We are currently examining palliative care outcomes in these domains and have found that outpatient palliative care significantly reduces suffering related to physical and emotional distress. Conclusions: Supportive care screening, can serve to reduce oncology readmissions and prevent patient suffering in six key palliative domains. During Phase II of the James Supportive Care Screening Model, we have identified several problem areas targeted to reduce readmissions and improve patient self-reported outcomes.
Risk of Arterial and Venous Thrombosis in 11,155 Patients with Myeloproliferative Neoplasms and 44,620 Matched Controls; A Population-Based Study
Authors: Malin Hultcrantz, Therese M-L Andersson, Ola Landgren, Asa Rangert Derolf, Paul W Dickman, Magnus Björkholm, Sigurdur Y Kristinsson
Journal: Blood (2014)
Cutaneous Presentation of Methicillin-Resistant<i>Staphylococcus aureus</i>Sepsis in a Healthy Child
Authors: Weston Wall, Caren Campbell, Soon Bahrami, Cindy Owen
Journal: JAMA Dermatology (2016)

Even among physically active women, 18% exercised less than they would like because of their hair, but almost half of the women did nothing specifically to preserve their hair during exercise.This may be due to the high percentage of women wearing their hair in natural styles in this study.In our previous study, 5 older women tended to wear their hair in natural styles compared with younger women.
MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
Authors: Hongkui Jin, Renhui Yang, Zhong Zheng, Mally Romero, Jed Ross, Hani Bou-Reslan, Richard A.D. Carano, Ian Kasman, Elaine Mai, Judy Young, Jiping Zha, Zemin Zhang, Sarajane Ross, Ralph Schwall, Gail Colbern, Mark Merchant
Journal: Cancer Research (2008)

Abstract The hepatocyte growth factor (HGF) and its receptor, c-Met, have been implicated in driving proliferation, invasion, and poor prognosis in pancreatic cancer. Here, we investigated the expression of HGF and c-Met in primary pancreatic cancers and described in vitro and in vivo models in which MetMAb, a monovalent antibody against c-Met, was evaluated. First, expression of HGF and MET mRNA was analyzed in 59 primary pancreatic cancers and 51 normal samples, showing that both factors are highly expressed in pancreatic cancer. We next examined HGF responsiveness in pancreatic cancer lines to select lines that proliferate in response to HGF. Based on these studies, two lines were selected for further in vivo model development: BxPC-3 (c-Met+, HGF−) and KP4 (c-Met+, HGF+) cells. As BxPC-3 cells are responsive to exogenous HGF, s.c. tumor xenografts were grown in a paracrine manner with purified human HGF provided by osmotic pumps, wherein MetMAb treatment significantly inhibited tumor growth. KP4 cells are autocrine for HGF and c-Met, and MetMAb strongly inhibited s.c. tumor growth. To better model pancreatic cancer and to enable long-term survival studies, an orthotopic model of KP4 was established. MetMAb significantly inhibited orthotopic KP4 tumor growth in 4-week studies monitored by ultrasound and also improved survival in 90-day studies. MetMAb significantly reduced c-Met phosphorylation in orthotopic KP4 tumors with a concomitant decrease in Ki-67 staining. These data suggest that the HGF/c-Met axis plays an important role in the progression of pancreatic cancer and that targeting c-Met therein may have therapeutic value. [Cancer Res 2008;68(11):4360–8]
Identification of new susceptibility loci for gastric non-cardia adenocarcinoma: pooled results from two Chinese genome-wide association studies
Authors: Zhaoming Wang, Juncheng Dai, Nan Hu, Xiaoping Miao, Christian C Abnet, Ming Yang, Neal D Freedman, Jinfei Chen, Laurie Burdette, Xun Zhu, Charles C Chung, Chuanli Ren, Sanford M Dawsey, Meilin Wang, Ti Ding, Jiangbo Du, Yu-Tang Gao, Rong Zhong, Carol Giffen, Wenting Pan, Woon-Puay Koh, Ningbing Dai, Linda M Liao, Caiwang Yan, You-Lin Qiao, Yue Jiang, Xiao-Ou Shu, Jiaping Chen, Chaoyu Wang, Hongxia Ma, Hua Su, Zhendong Zhang, Lemin Wang, Chen Wu, Yong-Bing Xiang, Zhibin Hu, Jian-Min Yuan, Lu Xie, Wei Zheng, Dongxin Lin, Stephen J Chanock, Yongyong Shi, Alisa M Goldstein, Guangfu Jin, Philip R Taylor, Hongbing Shen
Journal: Gut (2015)

<h3>Objective</h3> Although several genome-wide association studies (GWAS) of non-cardia gastric cancer have been published, more novel association signals could be exploited by combining individual studies together, which will further elucidate the genetic susceptibility of non-cardia gastric cancer. <h3>Design</h3> We conducted a meta-analysis of two published Chinese GWAS studies (2031 non-cardia gastric cancer cases and 4970 cancer-free controls) and followed by genotyping of additional 3564 cases and 4637 controls in two stages. <h3>Results</h3> The overall meta-analysis revealed two new association signals. The first was a novel locus at 5q14.3 and marked by rs7712641 (per-allele OR=0.84, 95% CI 0.80 to 0.88; p=1.21×10<sup>−11</sup>). This single-nucleotide polymorphism (SNP) marker maps to the intron of the long non-coding RNA, lnc-POLR3G-4 (<i>XLOC_004464</i>), which we observed has lower expression in non-cardia gastric tumour compared with matched normal tissue (P<sub>wilcoxon signed-rank</sub>=7.20×10<sup>−4</sup>). We also identified a new signal at the 1q22 locus, rs80142782 (per-allele OR=0.62; 95% CI 0.56 to 0.69; p=1.71×10<sup>−19</sup>), which was independent of the previously reported SNP at the same locus, rs4072037 (per-allele OR=0.74; 95% CI 0.69 to 0.79; p=6.28×10<sup>−17</sup>). Analysis of the new SNP conditioned on the known SNP showed that the new SNP remained genome-wide significant (P<sub>conditional</sub>=3.47×10<sup>−8</sup>). Interestingly, rs80142782 has a minor allele frequency of 0.05 in East Asians but is monomorphic in both European and African populations. <h3>Conclusion</h3> These findings add new evidence for inherited genetic susceptibility to non-cardia gastric cancer and provide further clues to its aetiology in the Han Chinese population.
Keratinization &lt;italic&gt;In Vitro&lt;/italic&gt; of Cells From a Basal Cell Carcinoma
Authors: B. Allen Flaxman, Eugene J. van Scott
Journal: JNCI Journal of the National Cancer Institute (1968)

Basal cell cancer (BCC) of the skin, comprised of germinativc cells showing no evidence of keratinization in vivo, when grown in vitro exhibits specific histologic and ultrastructural signs of keratinization. Non-keratinized cells are located centrally in the tumor expiants, and keratinized cells peripherally. The gradient and degree of keratinization in BCC in vitro are similar to those of normal epidermis in vivo and in vitro. The failure of BCC tumor cells to keratinize in vivo therefore seems to be a defect that is reversible.
Prophylactic oophorectomy in premenopausal women with non-metastatic colon cancer: A decision analysis
Authors: S. M. Mourton, J. P. Hollenberg, N. R. Abu-Rustum, D. S. Chi, W. D. Wong, L. K. Temple
Journal: Journal of Clinical Oncology (2006)

6130 Background: There is data to suggest that prophylactic oophorectomy (PO) in premenopausal women with colon cancer may improve survival. However, the potential for improved survival must be balanced against the trade-off of premature menopause and its affect on quality of life (QOL). The objective of this study was to determine the value of PO in premenopausal women undergoing surgical excision of colon cancer. Methods: We constructed a decision-analytic model comparing PO versus no PO for premenopausal women undergoing resection of stage I-III colon cancer. The model included detection of ovarian micrometastases (OMM), adjuvant chemotherapy, development of metachronous ovarian metastases, subsequent risk of ovarian cancer and QOL. Probabilities and utilities were estimated from published data. Life expectancy (LE) and quality adjusted LE (QALE) were calculated using the Declining Exponential Approximation of Life Expectancy. Results: With a baseline OMM incidence of 8%, a 5 yr survival of OMM removed (19%) vs OMM left in situ (11%), there was a gain in LE of 2.8 months with PO. With QOL adjustments for menopause (utility 0.77) and colon cancer (utility 0.37–0.85 ), QALE was 1.7 months less with PO. One-way sensitivity analysis (SA) demonstrated that the utility of menopause had the greatest effect on QALE differences, with a threshold value of 0.86 at which QALE was greater with PO. With increasing OMM incidence and 5-year survival with removed OMM, QALE became greater in the PO cohort. All 1, 2, and 3 way SAs demonstrated that the model was robust through the probable range of variables. Conclusions: Our model demonstrated the significant effect of menopause QOL on overall QALE. Although PO may lead to a small gain in LE, the trade-off of premature menopause must be considered when counseling patients. No significant financial relationships to disclose.
Clinical and pathological significance of FDG PET in follicular malignant lymphoma
Authors: R. P. Zekman, A. Ravipati, B. Tang, J. Malysz, V. Douglas, I. A. Jaiyesimi, P. Venuturumilli, O. C. Wong
Journal: Journal of Clinical Oncology (2008)

19517 Background: FDG PET is used widely for the staging of lymphoma, but few studies to date have evaluated FDG-PET in follicular lymphoma. We investigated whether FDG PET predicts bone marrow and splenic involvement in follicular lymphoma. To correlate metabolic behavior of follicular lymphoma (FL) with clinical and pathologic grading. Methods: Pre-treatment FDG PET scans of 23 pts (age=59±12) with pathologic diagnosis of FL were analyzed together with Ki67 and FLIPI score (FS). PET scans were obtained 1.5 hr after injection of average of 15 mCi of F-18 FDG with CT attenuation correlation. The glucose was recorded just before PET and the maximal SUVs were measured over biopsy region (BxSUV) and the highest tumor activity of the body (BmSUV). Bone marrow involvement (BMI) was defined by heterogenous marrow FDG uptake with histopathological correlation. Splenic involvement (SI) was defined as abnormal splenic uptake higher than the liver. Discriminant analysis was performed for BMI and SI against the independent variables of BmSUV and BxSUV. Results: Pathologic grading (PG) of FL was significantly correlated with Ki67 (p<0.01). BmSUV, Ki67 and FS were higher in PG III than PG I/II (p=0.032, 0.000 and 0.049). BmSUV and Bx SUV were also significantly correlated (p<0.01) though the means were different (11.5±6.3 vs 7.9±5.1), p<0.0005). BmSUV and Bx SUV classified correctly BMI with similar accuracies of 78% and 74% but BmSUV predicted better than BxSUV in SI at 78% and 65% respectively. There were no such predictions by PG, Ki67 or FS. Conclusions: BmSUV predicts BMI and SI with a higher value in PGIII than PG I/II FL. Clinician can consider using FDG PET in intial staging of FL. No significant financial relationships to disclose.